$OXBR
Oxbridge Re Holdings Ltd Stock $oxbr

$oxbr Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223016649 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$691.0K	$546.0K	$0.00
YoY Change	37.38%		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$677.0K	$404.0K	$338.0K
YoY Change	74.04%	19.53%	35.2%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.000K	$0.00	$2.000K
YoY Change	-95.24%	-100.0%	-33.33%
% of Gross Profit
Operating Expenses	$697.0K	$404.0K	$361.0K
YoY Change	70.0%	11.91%	32.72%
Operating Profit
YoY Change
Interest Expense	$5.000K	$76.00K	-$20.00K
YoY Change	-101.55%	-480.0%	-116.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$6.000K	$142.0K	-$361.0K
YoY Change	-106.45%	-139.34%	-868.09%
Income Tax			$26.00K
% Of Pretax Income
Net Earnings	-$85.00K	$142.0K	-$387.0K
YoY Change	-210.39%	-136.69%	-1482.14%
Net Earnings / Revenue	-12.3%	26.01%
Basic Earnings Per Share	-$0.01	$0.02	-$0.07
Diluted Earnings Per Share	-$0.01	$0.02	-$0.07
COMMON SHARES
Basic Shares Outstanding	5.870M shares	5.866M shares	5.751M shares
Diluted Shares Outstanding	5.870B shares	5.858M shares	5.751M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$3.117M	$729.0K	$5.148M
Short-Term Investments
Other Short-Term Assets	$135.0K	$252.0K
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$234.0K	$321.0K	$35.00K
YoY Change	260.0%	817.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.000K	$8.000K	$8.000K
YoY Change	0.0%	0.0%	-96.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$12.65M	$12.52M	$11.71M
YoY Change	4.11%	6.95%	650.51%
Other Assets	$372.0K	$2.891M	$2.172M
YoY Change	-82.89%	33.1%	-54.75%
Total Long-Term Assets	$18.47M	$16.53M	$17.12M
YoY Change	4.93%	-3.45%
TOTAL ASSETS
Total Short-Term Assets	$234.0K	$321.0K	$35.00K
Total Long-Term Assets	$18.47M	$16.53M	$17.12M
Total Assets	$18.71M	$16.85M	$17.15M
YoY Change	5.87%	-1.77%	94.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$216.0K
YoY Change
Accrued Expenses	$60.00K	$85.00K	$113.0K
YoY Change	-33.33%	-24.78%	-43.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$363.0K	$418.0K	$500.0K
YoY Change	-20.92%	-16.4%	21.95%
LONG-TERM LIABILITIES
Long-Term Debt	$118.0K	$172.0K	$216.0K
YoY Change	-45.37%	-20.37%	-1.82%
Other Long-Term Liabilities	$1.059M
YoY Change
Total Long-Term Liabilities	$1.177M	$172.0K	$216.0K
YoY Change	444.91%	-20.37%	-1.82%
TOTAL LIABILITIES
Total Short-Term Liabilities	$363.0K	$418.0K	$500.0K
Total Long-Term Liabilities	$1.177M	$172.0K	$216.0K
Total Liabilities	$3.553M	$1.663M	$856.0K
YoY Change	180.65%	94.28%	15.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$17.44M	-$17.36M	-$16.10M
YoY Change	8.81%	7.83%
Common Stock	$32.60M	$32.54M	$6.000K
YoY Change	0.5%	542266.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.16M	$15.19M	$16.30M
YoY Change
Total Liabilities & Shareholders Equity	$18.71M	$16.85M	$17.15M
YoY Change	5.87%	-1.77%	94.69%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$85.00K	$142.0K	-$387.0K
YoY Change	-210.39%	-136.69%	-1482.14%
Depreciation, Depletion And Amortization	$1.000K	$0.00	$2.000K
YoY Change	-95.24%	-100.0%	-33.33%
Cash From Operating Activities	-$1.474M	-$140.0K	-$69.00K
YoY Change	263.05%	102.9%	2.99%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$5.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$201.0K
YoY Change	-100.0%	-100.0%	-69.08%
Cash From Investing Activities	$0.00	-$5.000K	-$201.0K
YoY Change	-100.0%	-97.51%	-68.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.343M	-$163.0K
YoY Change
NET CHANGE
Cash From Operating Activities	-1.474M	-$140.0K	-$69.00K
Cash From Investing Activities	0.000	-$5.000K	-$201.0K
Cash From Financing Activities	1.343M	-$163.0K
Net Change In Cash	-131.0K	-$308.0K	-$270.0K
YoY Change	-77.45%	14.07%	-62.13%
FREE CASH FLOW
Cash From Operating Activities	-$1.474M	-$140.0K	-$69.00K
Capital Expenditures	$0.00	$5.000K
Free Cash Flow	-$1.474M	-$145.0K	-$69.00K
YoY Change		110.14%	2.99%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001584831
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet		usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2022Q1	us-gaap	Revenues Revenues		usd
CY2023Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts		usd
CY2023Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums		usd
CY2023Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2022Q1	OXBR	Proceeds From Repayments Of Offering Costs ProceedsFromRepaymentsOfOfferingCosts		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2022Q1	OXBR	Operating Lease Liability Non Cash OperatingLeaseLiabilityNonCash		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain		usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss		usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss		usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense		usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense		usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense		usd
CY2023Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense		usd
CY2022Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense		usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1		usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1		usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1		usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1		usd
CY2023Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1		usd
CY2022Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1		usd
CY2023Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense		usd
CY2022Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense		usd
CY2022Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense		usd
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2023Q1	OXBR	Shares Issuable Upon Conversion Of Warrants SharesIssuableUponConversionOfWarrants		shares
CY2022Q1	OXBR	Shares Issuable Upon Conversion Of Warrants SharesIssuableUponConversionOfWarrants		shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	1-36346
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	OXBRIDGE RE HOLDINGS LIMITED
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1150254
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 201
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	42 Edward Street, George Town
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	P.O. Box 469
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Grand Cayman
CY2023Q1	dei	Entity Address Country EntityAddressCountry	KY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-9006
CY2023Q1	dei	City Area Code CityAreaCode	(345)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	749-7570
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5870234	shares
CY2023Q1	OXBR	Fair Value Equity Securities Cost FairValueEquitySecuritiesCost	1926000	usd
CY2022Q4	OXBR	Fair Value Equity Securities Cost FairValueEquitySecuritiesCost	1926000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	718000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	642000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	729000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1207000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	381000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-230000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2891000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2721000	usd
CY2023Q1	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	144000	usd
CY2022Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	282000	usd
CY2023Q1	us-gaap	Other Investments OtherInvestments	11804000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	148000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	114000	usd
CY2023Q1	OXBR	Prepaid Offering Costs PrepaidOfferingCosts	252000	usd
CY2022Q4	OXBR	Prepaid Offering Costs PrepaidOfferingCosts	133000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	usd
CY2023Q1	us-gaap	Assets Assets	16848000	usd
CY2022Q4	us-gaap	Assets Assets	16616000	usd
CY2023Q1	us-gaap	Notes Payable NotesPayable	172000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	216000	usd
CY2023Q1	OXBR	Reserve For Loss And Loss Adjustment Expenses ReserveForLossAndLossAdjustmentExpenses	1073000	usd
CY2022Q4	OXBR	Reserve For Loss And Loss Adjustment Expenses ReserveForLossAndLossAdjustmentExpenses	1073000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	85000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	333000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	294000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1663000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1627000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5866234	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5866234	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5769587	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5769587	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	32536000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	32482000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17357000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17499000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15185000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14989000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16848000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16616000	usd
CY2022Q1	us-gaap	Premiums Earned Net PremiumsEarnedNet	210000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	76000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-20000	usd
CY2023Q1	us-gaap	Revenues Revenues	546000	usd
CY2022Q1	us-gaap	Deferred Policy Acquisition Cost Amortization Expense DeferredPolicyAcquisitionCostAmortizationExpense	23000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	404000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	338000	usd
CY2023Q1	us-gaap	Net Investment Income NetInvestmentIncome	89000	usd
CY2022Q1	us-gaap	Net Investment Income NetInvestmentIncome	33000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	7000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	404000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	361000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	65000	usd
CY2023Q1	OXBR	Operating Lease Liability Non Cash OperatingLeaseLiabilityNonCash	65000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	142000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-361000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	142000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-387000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5857643	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5751008	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	142000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-387000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	54000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	32000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2000	usd
CY2022Q1	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	7000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	381000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-230000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	76000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-20000	usd
CY2023Q1	us-gaap	Increase Decrease In Premiums Receivable IncreaseDecreaseInPremiumsReceivable	-138000	usd
CY2022Q1	us-gaap	Increase Decrease In Premiums Receivable IncreaseDecreaseInPremiumsReceivable	-280000	usd
CY2023Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	24000	usd
CY2022Q1	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	30000	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	-23000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	72000	usd
CY2022Q1	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-210000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	39000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	50000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-140000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69000	usd
CY2022Q1	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	409000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	208000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-201000	usd
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	44000	usd
CY2023Q1	OXBR	Proceeds From Repayments Of Offering Costs ProceedsFromRepaymentsOfOfferingCosts	119000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-163000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-308000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-270000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3928000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5418000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3620000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5148000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16651000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-387000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16296000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14989000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	142000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	142000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15185000	usd
CY2023Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_849_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zxmk49VxeJbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_86B_zULIsSCbKnCe">Reclassifications</span>: </span></b>Any reclassifications of prior period amounts have been made to conform to the current period presentation.</span></p>
CY2023Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	729000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1207000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2891000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2721000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	3620000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	3928000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	208000	usd
CY2022Q1	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	7000	usd
CY2021Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2000000	usd
CY2021Q3	OXBR	Capital Risk Percentage CapitalRiskPercentage	0.347	pure
CY2021Q3	OXBR	Ordinary Shares Percentage OrdinarySharesPercentage	0.496	pure
CY2021Q3	OXBR	Preferred Shares Percentage PreferredSharesPercentage	0.631	pure
CY2023Q1	OXBR	Fair Value Measurements Description FairValueMeasurementsDescription	The fair value calculation of the Company’s beneficial interest in OXAC’s Class B shares and Private Placement Warrants is dependent on company-specific adjustments applied to the observable trading prices of OXAC Class A ordinary shares and public warrants. The fair value calculation of the Company’s beneficial interest in the Extension Loan is dependent on company-specific adjustments applied to the pro-rata original principal amount of the Extension Loan. The Company’s management estimates that a specific discount of 25.11% sufficiently captures the risk or profit that a market participant would require as compensation for i) the lack of marketability of the Company’s beneficial interests in the OXAC and ii) assuming the inherent risk of forfeiture and default if a business combination doesn’t occur within OXAC’s stipulated time frame. The Company has selected a discount of 25.11% based on recent fair value measurements by an independent valuation expert, and due to the unobservable nature of this company-specific adjustment, the Company classifies the Other Investment as Level 3 in the fair value hierarchy. Subsequent changes in fair value will be recorded in the consolidated statement of operations during the period of the change.
CY2023Q1	OXBR	Unrealized Investment Gain Loss On Securities UnrealizedInvestmentGainLossOnSecurities	381000	usd
CY2022Q1	OXBR	Unrealized Investment Gain Loss On Securities UnrealizedInvestmentGainLossOnSecurities	230000	usd
CY2023Q1	us-gaap	Other Investments OtherInvestments	11804000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
CY2021Q4	us-gaap	Other Investments OtherInvestments	11173000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	381000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-230000	usd
CY2023Q1	us-gaap	Other Investments OtherInvestments	11804000	usd
CY2022Q1	us-gaap	Other Investments OtherInvestments	10943000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	729000	usd
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2891000	usd
CY2023Q1	us-gaap	Other Investments OtherInvestments	11804000	usd
CY2023Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	718000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	16142000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1207000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2721000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	642000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	15993000	usd
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.2511	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.2511	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	601250	shares
CY2023Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	44000	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	172000000	usd
CY2023Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<p id="xdx_895_eus-gaap--ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_zFfk9TVblE94" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s loss and loss adjustment expenses (“LAE”) and the reserve for loss and LAE reserve movements for the three month periods ending March 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B1_z2FH07qcggcg" style="display: none">SCHEDULE OF LOSS ADJUSTMENT EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20230101__20230331_z4i2Tw0iYyk9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20220101__20220331_zETnWr6V2uad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="text-align: center; font-weight: bold">At March 31,</td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">At March 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40C_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpense_iS_pn3n3_z6pWG9OGWFkd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Balance, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,073</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0607">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Incurred related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_pn3n3_maLFUCAzKTv_zaZCam2ikBf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0609">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0610">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_pn3n3_maLFUCAzKTv_zbMnnjTf4gx2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Prior period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0612">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0613">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_iT_pn3n3_mtLFUCAzKTv_zupoD5bl5rAe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total incurred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0615">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0616">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Paid related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_iN_pn3n3_di_maPFLALzSy6_zoUNXd2EqQ8i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0618">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0619">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_pn3n3_maPFLALzSy6_zCpCeLshnA32" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Prior period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0621">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0622">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--PaymentsForLossesAndLossAdjustmentExpense_iNT_pn3n3_di_mtPFLALzSy6_zJPR2lQh1e26" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0624">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpense_iE_pn3n3_zblXq1scy0g9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Balance, end of period</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,073</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0628">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1073000	usd
CY2023Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1073000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.44
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	142000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-387000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5857643	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5751008	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5857643	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5751008	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896250	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896250	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	871250	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.67
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846250	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	736875	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.43
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	35000	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	98000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P21M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	23000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.37
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	96647	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.37
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	16250	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	103397	shares
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.37
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	15000	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.80
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	32000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.80
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	3000	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	6.80
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	44000	shares
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	6.80
CY2023Q1	OXBR	Statutory Accounting Practice Statutory Capital And Surplus Required StatutoryAccountingPracticeStatutoryCapitalAndSurplusRequired	Under the terms of their respective licenses, Oxbridge Reinsurance Limited and Oxbridge Re NS are required to maintain a minimum and prescribed capital requirement of $500 in accordance with the relevant subsidiary’s approved business plan filed with CIMA.
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	24000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	24000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	24000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	24000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	85000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M25D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M1D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0770	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	79000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	40000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	88000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	85000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-016649-index-headers.html	Edgar Link	pending
0001493152-23-016649-index.html	Edgar Link	pending
0001493152-23-016649.txt	Edgar Link	pending
0001493152-23-016649-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oxbr-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
oxbr-20230331_cal.xml	Edgar Link	unprocessable
oxbr-20230331_def.xml	Edgar Link	unprocessable
oxbr-20230331_lab.xml	Edgar Link	unprocessable
oxbr-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OXBR
Oxbridge Re Holdings Ltd Stock $oxbr

2023 Q2 Form 10-Q Financial Statement

#000149315223016649 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OXBR Oxbridge Re Holdings Ltd Stock $oxbr

2023 Q2 Form 10-Q Financial Statement

#000149315223016649 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OXBR
Oxbridge Re Holdings Ltd Stock $oxbr